ArticleWorld journal of gastroenterology2011
Helicobacter pylori neutrophil activating protein as target for new drugs against H. pylori inflammation.
Article in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- A First-in-Human Phase 1 Randomized Single and Multiple Ascending Dose Study of RPh201 in Healthy Volunteers.Clinical pharmacology in drug development · 2020Trial
- Mastic gum as an adjunct therapy to standard bismuth quadruple therapy for Helicobacter pylori eradication: A randomized single-blind pilot study.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2026Article
- A vicious cycle inducer in gastric pathogenesis: implication of Helicobacter pylori.Archives of microbiology · 2026Review
- Differential cytokine expression in gastric tissues highlights helicobacter pylori's role in gastritis.Scientific reports · 2024Article
- Drug-Herb Interactions in the Elderly Patient with IBD: a Growing Concern.Current treatment options in gastroenterology · 2017Review
- Non-pharmacological treatment of Helicobacter pylori.World journal of gastrointestinal pharmacology and therapeutics · 2016Review
- Helicobacter pylori neutrophil-activating protein: from molecular pathogenesis to clinical applications.World journal of gastroenterology · 2014Review
- Serum Helicobacter pylori NapA antibody as a potential biomarker for gastric cancer.Scientific reports · 2014Article
- An infection-enhanced oncolytic adenovirus secreting H. pylori neutrophil-activating protein with therapeutic effects on neuroendocrine tumors.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- One-step chromatographic purification of Helicobacter pylori neutrophil-activating protein expressed in Bacillus subtilis.PloS one · 2013Article
- Complete genome sequence of Helicobacter cinaedi strain PAGU611, isolated in a case of human bacteremia.Journal of bacteriology · 2012Article
- Potential implications of Helicobacter pylori-related neutrophil-activating protein.World journal of gastroenterology · 2012Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Helicobacter pylori (H. pylori) infection is among the most common human infections and the major risk factor for peptic ulcer disease and gastric cancer. Within this work we present the implication of C-terminal region of H. pylori neutrophil activating protein in the stimulation of neutrophil activation as well as the evidence that the C-terminal region of H. pylori activating protein is indispensable for neutrophil adhesion to endothelial cells, a step necessary to H. pylori inflammation. In addition we show that arabino galactan proteins derived from chios mastic gum, the natural resin of the plant Pistacia lentiscus var. Chia inhibit neutrophil activation in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.